EQL Pharma is a generics- and speciality pharma company, dedicated to providing cost efficient pharmaceuticals for the Nordic markets. This is accomplished with the highest quality standards and streamlined logistic solutions.
Positive news concerning the pharmaceutical product Eletriptan EQL Pharma
The pharmaceutical product Eletriptan EQL Pharma was approved Monday within the framework of a decentralized procedure (a common approval procedure used when more than one country is involved). National approvals for Sweden and Denmark are expected within approximately a month.…
Zonisamid EQL Pharma launched in Denmark
Zonisamide EQL Pharma is an antiepileptic, used for the treatment of epilepsy. The original is called Zonegran (Eisai Limited).The total turnover of Zonisamid in Denmark is approximately SEK 10 million annually. Currently the original and 3 competitors are on the…
Report from the Annual General Meeting of EQL Pharma AB (publ) on May 15th, 2017
Adoption of the balance sheet and income statement, disposition regarding the Company’s results The annual general meeting resolved to adopt the balance sheet and income statement and the consolidated balance sheet and income statement for the financial year 2016. The…
- View all press releases